Top Markets
Coin of the day
Alimera Sciences, Inc. Alimera Sciences, Inc.

Alimera Sciences, Inc.

ALIM
Peringkat dalam Saham #26668
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and... Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Harga Saham
$5.54
Terakhir disinkronkan: 2024-09-18
Kapitalisasi Pasar
$38.76M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Alimera Sciences, Inc. (ALIM)

Kategori

Pendapatan untuk Alimera Sciences, Inc. (ALIM)
Pendapatan pada Jun 2024 TTM: $99.68M
Menurut laporan keuangan terbaru dari Alimera Sciences, Inc., pendapatan saat ini (TTM) adalah $99.68M. Pada tahun 2022, perusahaan menghasilkan pendapatan sebesar $54.13M penurunan dibandingkan dengan pendapatan pada tahun 2021 yang sebesar $59.03M. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Alimera Sciences, Inc. dari 2006 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
2026 (TTM) $99.68M 23.44%
2023 $80.75M 49.19%
2022 $54.13M -8.30%
2021 $59.03M 16.15%
2020 $50.82M -5.79%
2019 $53.94M 14.85%
2018 $46.97M 30.79%
2017 $35.91M 4.60%
2016 $34.33M 53.01%
2015 $22.44M 166.39%
2014 $8.42M 349.95%
2013 $1.87M 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
Pendapatan untuk perusahaan serupa atau pesaing